Table 1.
Effect of bempedoic acid on other lipid parameters [39]
| Endpoint | Placebo-corrected difference in LS mean percent change from baseline at week 12 (95% CI) | |
|---|---|---|
| ASCVD/HeFH on statins pool | Statin intolerant pool | |
| Non-HDL-C |
−13.1% (−14.7 to −11.6) p < 0.001 |
−20.4% (−23.4 to −17.5) p < 0.001 |
| TC |
−11.1% (−12.2 to −9.9) p < 0.001 |
−16.2% (−18.4 to −13.9) p < 0.001 |
| ApoB |
−12.1% (−13.6 to −10.7) p < 0.001 |
−16.9% (−19.6 to –14.2) p < 0.001 |
ApoB apolipoprotein B, 95% CI 95% confidence interval, non-HDL-C non-high-density lipoprotein cholesterol, LS least squares, TC total cholesterol